A comparative overview of SSRI-sertraline and SNRI-desvenlafaxine
1 Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
2 Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Review
International Journal of Scholarly Research in Multidisciplinary Studies, 2023, 03(01), 016–021.
Article DOI: 10.56781/ijsrms.2023.3.1.0072
Publication history:
Received on 27 May 2023; revised on 04 July 2023; accepted on 07 July 2023
Abstract:
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. The common features of all the depressive disorders are sadness, emptiness, or irritable mood, accompanied by somatic and cognitive changes that significantly affect the individual’s capacity to function. Depression is commonly treated in primary care, and SSRI drugs are frequently used as the first line of treatment. Selective Serotonin Reuptake Inhibitors (SSRIs) have the advantage of the ease of dosing and low toxicity in overdose. They are also the first-line medications for late-onset depression. Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), which include venlafaxine, desvenlafaxine, duloxetine, and levomilnacipran can be used as first-line agents, particularly in patients with significant fatigue or pain syndromes associated with the episode of depression. SNRIs also have an important role as second-line agents in patients who have not responded to SSRIs. The pharmacokinetics, pharmacodynamics, uses, side effects, and contraindications of desvenlafaxine, an SNRI, and sertraline, an SSRI are compared in this article.
Keywords:
Depression; Desvenlafaxine; Sertraline; Efficacy; Safety; Selective serotonin and norepinephrine reuptake inhibitors; Selective serotonin reuptake inhibitors
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0